Literature DB >> 20724798

Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs.

Xuhan Liu1, Guosheng Li, Hua Zhu, Lan Huang, Yali Liu, Chunmei Ma, Chuan Qin.   

Abstract

The "lipotoxicity" hypothesis holds that fat-induced hepatic insulin resistance (FIHIR) may play a major role in the pathogenesis of type 2 diabetes. Berberine has been reported to have antidiabetic properties. However, the molecular mechanisms for this action are not fully clarified. Therefore, we will investigate the gene expression alterations involved in the therapeutic effect of berberine on FIHIR in diabetic hamsters and possible mechanisms. In this study, type 2 diabetic hamsters were induced by high-fat diet with streptozotocin injection. After 9 weeks of berberine-treatment, the gene expression alterations involved in the therapeutic molecular mechanisms of berberine on FIHIR will be studied by microarray technology and real time RT-PCR. Our study demonstrates berberine significantly improved fat-induced insulin resistance and diabetic phenotype in type 2 diabetic hamsters. The alterations of certain metabolism related genes and their main regulators: Liver X receptor (LXR) α, Peroxisome proliferator-activated receptor (PPAR) α and Sterol regulatory element-binding protein (SREBPs) are observed in the liver of treated and untreated diabetic hamsters. Compared with diabetic hamsters, the increased mRNA levels of LXRα and PPARα and the decreased mRNA levels of SREBPs are observed in berberine-treated diabetic hamster. The statistical significance of the expression of hepatic LXRα, SREBPs and PPARα and their certain target genes is found between treated and untreated diabetic hamsters. These results suggest that altered hepatic SREBPs, LXRα and PPARα transcriptional programs possibly involve in the therapeutic mechanisms of berberine on FIHIR in type 2 diabetic hamsters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724798     DOI: 10.1507/endocrj.k10e-043

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  17 in total

1.  Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice.

Authors:  Ying Guo; Chad Pope; Xingguo Cheng; Honghao Zhou; Curtis D Klaassen
Journal:  J Ethnopharmacol       Date:  2011-09-06       Impact factor: 4.360

2.  Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue.

Authors:  C Hu; X D Cong; De-Zai Dai; Y Zhang; G L Zhang; Y Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

Review 3.  HDL and cognition in neurodegenerative disorders.

Authors:  David A Hottman; Dustin Chernick; Shaowu Cheng; Zhe Wang; Ling Li
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

4.  Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.

Authors:  Shu-Jun Jiang; Hui Dong; Jing-Bin Li; Li-Jun Xu; Xin Zou; Kai-Fu Wang; Fu-Er Lu; Ping Yi
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

5.  Anti-cancer natural products isolated from chinese medicinal herbs.

Authors:  Wen Tan; Jinjian Lu; Mingqing Huang; Yingbo Li; Meiwan Chen; Guosheng Wu; Jian Gong; Zhangfeng Zhong; Zengtao Xu; Yuanye Dang; Jiajie Guo; Xiuping Chen; Yitao Wang
Journal:  Chin Med       Date:  2011-07-22       Impact factor: 5.455

Review 6.  Berberine hydrochloride: anticancer activity and nanoparticulate delivery system.

Authors:  Wen Tan; Yingbo Li; Meiwan Chen; Yitao Wang
Journal:  Int J Nanomedicine       Date:  2011-08-24

7.  In Vivo and In Vitro Analysis in Coronary Artery Disease Related to Type 2 Diabetes.

Authors:  Teresa Infante; Ernesto Forte; Marco Aiello; Marco Salvatore; Carlo Cavaliere
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-21       Impact factor: 5.555

Review 8.  Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis.

Authors:  Yanwen Wang; Jeffrey A Zidichouski
Journal:  Cholesterol       Date:  2018-07-02

9.  Update on berberine in nonalcoholic Fatty liver disease.

Authors:  Yang Liu; Li Zhang; Haiyan Song; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-17       Impact factor: 2.629

Review 10.  The antihyperglycemic effects of Rhizoma Coptidis and mechanism of actions: a review of systematic reviews and pharmacological research.

Authors:  Hui Wang; Wei Mu; Hongcai Shang; Jia Lin; Xiang Lei
Journal:  Biomed Res Int       Date:  2014-04-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.